Variables and Strategies in Development of Therapeutic Post-Transcriptional Gene Silencing Agents
Figure 7
Comparison of mutation independent and mutation dependent strategies to PTGS therapy. The schematic representation shows two folded mRNAs, one in which a MD strategy is being used to attack discrete mutations which obligate the site of attack to regions that are likely to be buried, and the other is an MI strategy, where the best (most accessible) NUH (lavender) or RNAi cleavage site is sought for use. This challenge applies to hhRz or RNAi type therapeutics.
